Tests showed new generation of drug that frees immune system to attack devastating form of lung cancer doubled life expectancy of certain patients
A drug that frees the immune system to attack a devastating form of lung cancer has been shown to double the life expectancy of a targeted group of patients.
Nivolumab is one of new generation of immunotherapy drugs that release cancer-applied brakes on the immune system called “checkpoints”. The results, from an international trial involving patients who had already been treated for the most common form of lung cancer, were described by one expert as a “paradigm shift”.
Continue reading...
No comments:
Post a Comment